FDA Considers Toxicity Profiles As Meeting Unmet Need In Melanoma
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline’s Mekinist (trametinib) and Tafinlar (dabrafenib) qualified for the regulatory benefits afforded drugs that address unmet medical needs under a broad theory introduced in FDA’s draft guidance on expedited approval pathways: offering different, but not necessarily better, toxicity profiles than marketed drugs was seen as an advantage.
You may also be interested in...
The Magnitude Matters: GSK Approvals Show How To Use PFS After Other Drugs Show Survival
Submitting an NDA based on progression-free survival when other drugs for the indication have been approved on the basis of overall survival benefits is a risky proposition, but GlaxoSmithKline was confident the magnitude of Mekinist and Tafinlar’s PFS effect in metastatic melanoma would make the findings clinically relevant.
The Next Phase In Oncology: FDA’s Pazdur Has New Vision For Drug Development
FDA’s top cancer drug reviewer has taken to the podium to paint a picture of the next phase in cancer drug development, which includes new business models, a return to single-arm trials and a new emphasis on safety.
Co-Development Guidance Gives More Attention To IND, NDA/BLA Submissions
In a final guidance on co-development of two or more investigational new drugs for use in combination, FDA lays out general principles for IND and marketing application submissions, a topic on which the agency essentially punted in a December 2010 draft document.